-
NMPA grants conditional approval to CanSino’s recombinant COVID-19 vaccine
2021-02-27
The National Medical Products Administration (NMPA) conditionally approved the registration application of the recombinant COVID-19 vaccine (adenovirus type-5-vectored vaccine) developed by CanSino Biologics on Feb 25.
-
NMPA conditionally approves COVID-19 vaccine developed by Sinopharm's Wuhan institute
2021-02-27
The National Medical Products Administration (NMPA) conditionally approved the registration application of the inactivated COVID-19 vaccine (Vero cell) developed by the Wuhan Institute of Biological Products administered by Sinopharm on Feb 25.
-
Chinese mainland reports no new locally transmitted COVID-19 cases
2021-02-26
The Chinese mainland reported no new locally transmitted COVID-19 cases on Thursday, the National Health Commission said on Feb 26.
-
Chinese mainland reports no new locally transmitted COVID-19 cases
2021-02-25
The Chinese mainland reported no new locally transmitted COVID-19 cases on Wednesday, the National Health Commission said on Feb 25.
-
Chongqing approved as port of entry for imported drugs
2021-02-25
China's Chongqing municipality has been approved as a port of entry for imported drugs, making it the only such entry port in west China and the fourth in the Chinese mainland following Beijing, Shanghai and Guangzhou.
-
Two Chinese-developed COVID-19 vaccines under review
2021-02-25
Two more homegrown COVID-19 vaccines are being reviewed by China's top drug regulator to obtain conditional market approval, the drugmakers announced on Feb 24.
